Because of their immunomodulatory and engraftmentpromoting properties, mesenchymal stromal cells (MSCs) have been tested in the clinical setting both to facilitate haematopoietic recovery and to treat steroid-resistant acute GVHD. More recently, experimental findings and clinical trials have focused on the ability of MSCs to home to damaged tissue and to produce paracrine factors with antiinflammatory properties, resulting in functional recovery of the damaged tissue. The mechanisms through which MSCs exert their therapeutic potential rely on some key properties of the cells: the ability to secrete soluble factors capable of stimulating survival and recovery of injured cells; the capacity to home to sites of damage and the ability to blunt exaggerated immune responses. These fundamental properties are being tested within a novel therapeutic field defined as Regenerative Medicine. This review deals with recent research on the anti-inflammatory/reparative properties of MSCs and considers the possible mechanisms of function responsible for these effects. Moreover, current and potential clinical applications of MSC-based treatment strategies in the context of Regenerative Medicine are being discussed. Key issues such as optimal timing of MSC administration, cell dose and schedule of administration, advantages and disadvantages of using autologous or allogeneic cells are still open. Nonetheless, MSCs promise to represent a revolution for many severe or presently untreatable disorders.
Introduction
Mesenchymal stromal cells (MSCs) were first described as a population of adherent cells, isolated from BM, which were non-phagocytic, exhibited a fibroblast-like appearance and could differentiate in vitro into bone, cartilage, adipose tissue, tendon and muscle. 1 Moreover, after transplantation under the kidney capsule, these cells gave rise to the different connective tissue lineages. 2 It was subsequently shown that MSCs can be relatively easily isolated not only from BM, but also from other tissues (that is, adipose tissue, umbilical cord blood, placenta, dental pulp) and that they display a remarkable capacity for extensive in vitro expansion to numbers that allow in vivo therapeutic use. [3] [4] [5] On the basis of their multilineage differentiation capacity, MSCs were first considered as a therapeutic tool for treatment of bone and cartilage diseases. The ability of MSCs to repair bone and cartilage was initially demonstrated in pre-clinical studies, 6, 7 and the promising results obtained paved the way to the execution of clinical trials using MSCs to treat large bone defects and articular cartilage defects. [8] [9] [10] Therapeutic infusion of MSCs has been also used in the context of Osteogenesis Imperfecta (OI), a severe genetic disease characterized by production of defective type I collagen, which is responsible for the occurrence of fractures and retarded bone growth. MSC administration in this disease was demonstrated to lead to an amelioration of the clinical conditions of the treated patients, with a reduction of the number of fractures and an improvement of patient growth. 11, 12 More recently, experimental findings and clinical trials have focused on the ability of MSCs to home to sites of damage in response to tissue injury and to promote repair through the production of trophic factors, resulting in reduction of inflammation and functional recovery of damaged tissue. On the basis of encouraging preliminary findings, potential clinical application of MSCs is being explored within a novel medical field, defined as Regenerative Medicine. Indeed, MSCs might become a potentially efficacious tool in the therapeutic options available to treat and cure several degenerative disorders, in particular those requiring the repair of damaged tissues together with an anti-inflammatory effect.
This review focuses on recent experimental and clinical findings related to MSCs, highlighting their role in promoting tissue repair, and discussing the potential clinical applications of MSC-based treatment strategies in the context of Regenerative Medicine.
In vivo regenerative properties of MSCs in animal models
In vivo animal models Thanks to their ability to home to inflamed sites and to repair injured tissues, together with their immunomodulatory and anti-inflammatory properties, MSCs have been tested in several animal models of tissue injury and degenerative disorders (see Table 1 ). In detail, murine MSCs have been demonstrated to ameliorate experimental autoimmune encephalomyelitis, a model of post-vaccinal encephalitis with many aspects resembling those of human multiple sclerosis, through the induction of peripheral T-cell tolerance against the central nervous system (CNS)-restricted Ags. 13, 14 In a murine model of systemic lupus erythematosus, MSCs were able to inhibit autoreactive T and B cells, thus ameliorating the signs and symptoms of the disease. 15 MSCs have been also used for the experimental treatment of diabetes in a mouse model and their infusion was associated with an increase in the number of pancreatic islets and insulin-producing b cells, as well as with the repair of renal glomeruli. 16 Moreover, the administration of congeneic MSCs in a murine model of type 1 diabetes was shown to suppress both diabetogenic T-cell proliferation and generation of myeloid/inflammatory DCs, resulting in long-term reversal of hyperglycemia. 17, 18 The infusion of rat MSCs in an experimental model of glomerulonephritis was able to stimulate glomerular healing, this resulting into the repair of the damaged renal tissue. 19 I.v. infusion of MSCs in immunodeficient mice with cisplatin-induced acute kidney injury ameliorated both renal function and tubular cell injury, and prolonged survival due to the inhibition of oxidative damage. 20, 21 Besides autoimmune encephalomyelitis, infusion of MSCs have been demonstrated to have a role in the protection of neurons from damage occurring in conditions such as spinal cord injury, stroke and degenerative conditions. [22] [23] [24] [25] Topical implantation of BM-derived MSCs has been shown to be beneficial in promoting the healing process of experimental colitis in rats, confirming the ability of these cells to induce tissue repair. 26 In similar models of experimental colitis, MSCs of different tissue origin alleviated the signs and symptoms of the disease by displaying immunomodulatory functions and ameliorating inflammation-related tissue destruction. 27, 28 A protective/reparative effect of MSCs was also noted, despite limited engraftment, in a murine model of endotoxin-induced acute lung injury, and this was associated with improved animal survival. 29 This finding was confirmed in an ex vivo perfused human lung preparation, where allogeneic human MSCs were capable of repairing E. coli endotoxin-induced acute lung injury. 30 In a rat model, MSC-derived conditioned medium proved effective in reversing fulminant hepatic failure, suggesting that MSC-derived molecules are able to promote regeneration of hepatocytes. 31, 32 Recent pre-clinical studies have suggested that MSCs could be used to mediate cardiac repair after myocardial infarction (MI), as well as after chronic progressive cardiac failure. In particular, human MSCs have been shown to differentiate into cells with a cardiomyocyte phenotype in the adult murine heart 33 and to improve cardiac function after transplantation in porcine and rat models. 34, 35 Although the vast majority of reports indicate a favorable role of MSCs in the promotion of tissue repair, a few studies did not confirm the ability of these cells to display an anti-inflammatory/protective effect. For example, infusion of MSCs had no beneficial effects on collagen-induced arthritis when tested in a murine model of rheumatoid arthritis; in particular, MSC treatment was associated with an accentuation of Th1 response, although MSCs could not be detected in the articular environment. 36 In vitro, in a MLC system, MSCs were unable to inhibit the proliferation of allogeneic T cells when cultured in the presence of TNF-a, a cytokine known to have a central role in the inflammatory cascade involving rheumatoid arthritis. As the addition of MSCs was associated with an increase in the levels of IL-6 in the cultures, it is reasonable to speculate that the high levels of IL-6 in the presence of TNF-a were responsible for the absence of a beneficial effect of MSCs in this murine model of collagen-induced arthritis. 36 
MSC mechanisms of function
The mechanisms through which MSCs exert their therapeutic potential in tissue repair, although not fully defined, might rely on some fundamental key properties of these cells: (i) their ability to secrete soluble factors capable to Table 1 In vivo animal models of MSC infusion for tissue repair
Mouse, EAE Prevention of EAE development 13, 14 Mouse, SLE Ameliorated signs and symptoms of SLE 15 Mouse, STZ diabetes Ameliorated diabetes and kidney disease [16] [17] [18] Rat, glomerulonephritis Stimulated glomerular healing 17 Mouse, AKI Ameliorated renal function and tubular cell injury 20, 21 Spinal cord injury, stroke Displayed protection of neurons from damage [22] [23] [24] [25] Rat, experimental colitis Stimulated intestinal mucosa healing [26] [27] [28] Mouse, endotoxin-induced acute lung injury Improved animal survival 29 Rat, acute hepatic failure Protected against hepatic injury 31, 32 Mouse, rat, pig, myocardial infarction Improved cardiac function [33] [34] [35] Mouse, CIA No beneficial effect; accentuation of Th1 response 36 Abbreviations: AKI ¼ acute kidney injury; CIA ¼ collagen-induced arthritis; EAE ¼ experimental autoimmune encephalomyelitis; SLE ¼ systemic lupus erythematosus; STZ ¼ streptozotocin.
stimulate survival and functional recovery of injured cells; (ii) the ability to home to sites of damage; and (iii) the ability to modulate immune responses. Indeed, in most of the reported studies, the therapeutic effect of MSCs did not seem to be associated with their differentiation into the resident cell types, but seemed to be mostly related to their anti-proliferative and anti-inflammatory effect, as well as to their capacity to stimulate survival and functional recovery in injured organs, likely through paracrine mechanisms. [19] [20] [21] 31, 32 It is possible that the therapeutic benefit is a result of the release of soluble factors and chemokines (such as hepatocyte growth factor, insulin-like growth factor, prostaglandin E2, nitric oxide) produced by the cells and/or by the local microenvironment, and that MSC survival be not necessary for their clinical effect. 31, 32 Moreover, experimental and clinical data obtained so far indicate that a sustained engraftment of MSCs within the damaged organ is not required in most cases for a meaningful effect or it is limited to a small number of cells. In this regard, studies in baboons using a green fluorescent retroviral construct suggest engraftment of MSCs in the gastro-intestinal tract and in various tissues in the range of 0.1-2.7%, with comparable results for autologous and allogeneic cells. 37 Although little is known of MSC homing to target tissues after infusion, it might depend on cytokines, chemokines and growth factors released during systemic and/or local inflammatory conditions and might be mediated by interaction with integrins and selectins expressed on the surface of MSCs. The intrinsic ability of MSCs to home to inflamed and ischemic tissues would significantly increase the feasibility of cellular therapy in the setting of inflammatory diseases and tissue repair. Wynn et al. 38 showed that homing of MSCs to BM depends on stromal-derived factor-1 (SDF-1) that interacts with CXCR4 on the MSC surface, thus promoting their migration. Similar mechanisms have been shown to regulate migration of MSCs to pancreatic islets 39 and ischemic tissues. 40 The inhibition of inflammatory and immune responses by MSCs might also be displayed through the generation of regulatory T cells, as shown in an experimental murine model of Crohn's Disease (CD), in which MSC infusion was efficacious in both preventing and curing colitis, probably through the induction of FoxP3 þ regulatory T cells. 41 Whether different MSC subsets are responsible for different effects in vivo (that is, reparative, immunomodulatory, anti-proliferative and engraftment-promoting) is still an open question and a matter of intensive investigation. 42 Intrinsic diversities of MSCs residing in different tissues, as well as their physiological role in a specific tissue, might explain the properties of a specific tissue source, as compared with other sources. 43 Also
Clinical applications of MSCs in Regenerative Medicine
Following the numerous reports showing a beneficial effect of MSC treatment in experimental models of autoimmunity and acute tissue injury, clinical data on the use of MSCs in Regenerative Medicine within phase I/II trials have become available (see Table 2 ).
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Metachromatic leukodystrophy and Hurler disease As MSCs produce high levels of arylsulfatase A and alfa-L-iduronidase, MSC treatment has been proposed for patients affected by metachromatic leukodystrophy and Hurler disease, two inherited diseases caused by the deficiency of the above mentioned enzymes. In a report from Koc et al., 44 donor-derived MSCs were infused in 11 patients with metachromatic leukodystrophy and Hurler disease after allogeneic HSCT. Although there was no major improvement in the overall health of the patients, in four of five children with metachromatic leukodystrophy an improvement in nerve-conduction velocity was observed. 
Neurodegenerative disorders
A phase I clinical study including 10 patients affected by multiple sclerosis and treated with autologous MSC infusion has been published, demonstrating the feasibility and the safety of the approach. 45 In 15 patients affected by multiple sclerosis and 19 patients with amyotrophic lateral sclerosis treated with intrathecal and/or i.v. MSC infusion, the procedure resulted to be safe and was associated with an increase in the proportion of CD4 þ CD25 þ regulatory T cells in the peripheral blood of the patients. 46 Recently, an International Panel comprising both multiple sclerosis and stem cell experts has been formed with the aim of reaching a consensus and designing protocols on the use of MSCs for the treatment of multiple sclerosis, as well as for standardizing the method of MSC expansion to be used in this setting. 47 Moreover, i.v. infusion of autologous MSCs has been tested in patients with stroke and it was demonstrated to be a feasible and safe therapy, which may improve functional recovery of the damaged cells. 48 MSC-based cellular therapy was also applied for the treatment of spinal cord injury in a pilot study. 49 Despite the numerous clinical trials being developed for MSC use in neurodegenerative disorders, a clear evidence of their neurogenic reparative potential, either through a trophic or an immunomodulatory effect, is lacking.
Inflammatory bowel diseases
As far as inflammatory bowel diseases are concerned, in a phase I clinical trial, autologous, adipose tissue-derived MSCs have been successfully used to treat complex perianal fistulas of cryptoglandular origin or associated with CD with promising results. 50 Recently, our group has demonstrated that sustained closure of fistula tracks, together with a parallel reduction of CD and perianal disease activity indexes, can be obtained in patients with refractory fistulizing CD through local injections of autologous BMderived MSCs. 51 In another phase I/II study, i.v. infusion of autologous MSCs proved to be feasible and safe in nine patients with CD refractory to conventional treatments, three of them showing clinical response. 52 In these latter two papers, an increase in regulatory FoxP3 þ T cells in mucosal biopsies was found after MSC treatment, as compared with what observed before treatment initiation. 51, 52 Moreover, Duijvenstein et al. 52 determined the levels of inflammatory cytokines such as TNF-a, IL-1, IL-10 and IL-6 in mucosal biopsies and found that they were decreased after MSC treatment, highlighting the role of MSC in inhibiting inflammation and promoting functional recovery of mucosal resident cells.
Myocardial infarction
Following the promising experimental results of MSC treatment in animal models of MI, a randomized placebocontrolled clinical trial has been conducted in patients within 10 days following acute MI. 53 Patients receiving MSC i.v. infusion experienced an improvement in overall health as compared with patients treated with placebo, coupled with an increase of left ventricular ejection fraction at 1 year after the treatment. However, patients treated with intracoronary administration of MSCs after MI did not maintain a significant improvement in left ventricular ejection fraction over controls at the 18 months follow-up evaluation. 54 The heterogeneity in the route of administration, timing of MSC infusion after MI and number of cells administered do not allow for definitive conclusions on this approach. This underlines the importance of implementing large multicenter randomized studies and collecting data on long-term follow-up before concluding that this novel treatment strategy has real efficacy in the setting of both acute MI and chronic progressive cardiac disease. Moreover, adverse events, such as undesired bone formation in the infarcted heart, 55 should be closely monitored after MSC treatment.
Liver diseases
In regard to liver diseases, MSCs have been used to treat cirrhosis in a limited number of patients likely thanks to their ability to regulate the fibrotic process and to display an anti-fibrotic effect. Kharaziha et al. 56 reported a phase I-II clinical trial in that eight patients with end-stage liver cirrhosis were treated with autologous injection of MSCs via either a peripheral vein or the portal vein; these preliminary results confirm the safety of the approach and suggest some improvement in the clinical conditions of the patients. Similar findings were obtained by Mohamadnejad et al. 57, 58 who also showed that MSCs are superior to hematopoietic stem cells in treating liver cirrhosis.
Future uses of MSCs
Discussion is underway also concerning the treatment with MSCs of other autoimmune and inflammatory disorders, such as type 1 diabetes mellitus, systemic sclerosis and systemic lupus erythematosus, acute kidney injury, gastrointestinal (autoimmune enteropathy) and pulmonary (chronic obstructive pulmonary disease) disorders (see also Table 3 ). [59] [60] [61] [62] [63] [64] Thanks to the promising experimental results in animal models of diabetes in terms of both increased insulin production and repair of renal glomeruli, [16] [17] [18] clinical trials with MSCs are being discussed and developed for this disease. Recently, MSCs have been tested in patients affected by refractory systemic lupus erythematosus, their infusion being associated with an improvement in both serological markers of the disease and renal function. 61 MSC therapy could also have a role in renal diseases, such as those characterized by acute renal damage (that is, acute kidney injury), and in patients undergoing kidney transplantation either to facilitate graft acceptance or to prevent long-term post-transplant complications related to the prolonged administration of immunosuppressive drugs. 62 The anti-fibrotic and reparative role of MSCs in lung diseases, such as acute lung injury and chronic obstructive pulmonary disease, is also being discussed and considered for clinical trials. 63 A total of 11 patients affected by a radiation-induced lung injury have been treated with autologous MSCs with promising preliminary results. 63 Finally, MSCs could be used in the treatment of wounds with the aim to accelerate their healing process; in particular, local injections of MSCs have been proposed as a therapeutic tool in diabetic foot, severe limb ischemia and radiationinduced wounds.
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Autologous vs allogeneic MSCs
Whether autologous or allogeneic MSCs should be preferred in the setting of Regenerative Medicine needs to be further investigated. It is reasonable to speculate that in autoimmune and chronic inflammatory disorders, in which sufficient time for MSC harvest and ex vivo expansion is available, autologous cells may be preferentially used, provided that they are functionally active, also in view of the potential immunogenicity of allogeneic cells.
However, contradictory results have been published on the properties of ex vivo expanded MSCs from patients affected by autoimmune and chronic inflammatory diseases. [68] [69] [70] In particular, MSCs isolated from patients with systemic sclerosis have been reported to be functionally impaired in vitro; while, other reports have documented that MSCs of systemic sclerosis patients, as well as those from patients with various autoimmune diseases, exhibit comparable phenotypical and functional properties of their healthy counterparts. [68] [69] [70] In particular, it has been demonstrated that MSCs isolated from BM of patients affected by refractory CD show the typical morphology, immune phenotype, differentiation and immunomodulatory properties of MSCs cultured from healthy donors, 52, 70 suggesting that patient-derived MSCs, rather than third party cells, could be used in such non-profoundly immunodepressed subjects. Indeed, in patients affected by inflammatory and degenerative disorders the use of autologous MSCs might offer significant advantages over allogeneic cells, which might be rejected after infusion without having the chance to display their beneficial tissue-healing effect. However, whether 'diseased' MSCs isolated from patients affected by different degenerative and autoimmune diseases are functionally impaired or whether they display similar characteristics as those of healthy donors needs to be further investigated.
Conclusions
The clinical trials conducted so far in the context of Regenerative Medicine suggest that clinical use of MSCs is feasible and safe. To date, no severe adverse reactions have been recorded in humans after MSC administration, both in terms of immediate, infusional toxicity and of late effects; however, longer follow-up is necessary to draw definitive conclusions on potential long-term adverse events (in particular, ectopic tissue and tumor formation). 55, 71, 72 Although the efficacy of MSC therapy has been suggested in many of the settings tested so far, well-designed controlled trials are warranted to properly establish the role of MSC therapy in comparison with more conventional treatment modalities.
Moreover, to completely exploit the potentiality of MSCs as a novel therapeutic tool in Regenerative Medicine more in vivo experimental work is required to increase the knowledge on how MSCs mediate their protective/reparative effect and reduce inflammatory responses. Future research should also include the identication of MSCspecific markers. Although recently many research groups have reported the identification of new MSC markers, [73] [74] [75] none of the available techniques has demonstrated to be singularly capable of identifying the true mesenchymal progenitors. Moreover, microarray studies should reveal some of the molecular pathways and genes responsible for either commitment of MSCs along a specific lineage or for their maintenance in an undifferentiated state. 76, 77 Optimal timing of MSC administration, cell dose and schedule of administration need to be defined. In chronic inflammatory and autoimmune diseases, MSCs might not be a 'once-in-a-life treatment', but could represent a helpful tool during the active and severe phases of the disease. The question whether the simultaneous administration of other immunosuppressive treatments could either potentiate or abolish MSC therapeutic benefit needs also to be addressed in future experimental and clinical studies.
Once more precisely defined, the anti-inflammatory/ reparative properties of MSCs might be efficaciously used as a novel therapeutic tool to enhance tissue repair and blunt exaggerated inflammation in approaches of Regenerative Medicine. 
Diabetes
Increased insulin production; repair of renal glomeruli [16] [17] [18] Refractory SLE Immunomodulatory and anti-inflammatory effect 61 Acute renal damage (AKI) Stimulate glomeral/tubular healing, inhibit oxidative damage 62 Kidney transplantation Immunomodulatory effect, prevent graft rejection 62 Acute lung injury Anti-inflammatory and anti-fibrotic effect 63 Wound healing (diabetic foot, severe limb ischemia, radiation injury) Anti-inflammatory effect, stimulate functional recovery [64] [65] [66] [67] Abbreviations: AKI ¼ acute kidney injury; SLE ¼ systemic lupus erythematosus.
Progetti di Rilevante Interesse Nazionale, PRIN), from Associazione Italiana per la Ricerca sul Cancro (AIRC) IG9062 to MEB and by the special grant '5x1000' from AIRC to FL.
